McIntosh Rachel L, Mohamed Quresh, Saw Seang Mei, Wong Tien Yin
Centre for Eye Research Australia, University of Melbourne, Melbourne, VIC, Australia.
Ophthalmology. 2007 May;114(5):835-54. doi: 10.1016/j.ophtha.2007.01.010. Epub 2007 Mar 30.
To assess the evidence on interventions to improve visual acuity (VA) and to treat macular edema and/or neovascularization secondary to branch retinal vein occlusion (BRVO).
Branch retinal vein occlusion is the second most common retinal vascular disease.
METHODS/LITERATURE REVIEWED: English and non-English articles were retrieved using a keyword search of Medline (1966 onwards), Embase, the Cochrane Collaboration, the National Institute of Health Clinical Trials Database, and the Association for Research in Vision and Ophthalmology Annual Meeting Abstract Database (2003-2005). This was supplemented by hand searching references of review articles. Two investigators independently identified all randomized clinical trials (RCTs) with more than 3 months' follow-up.
From 4332 citations retrieved, 12 RCTs were identified. There were 5 RCTs on laser photocoagulation. Grid macular laser photocoagulation was effective in improving VA in 1 large multicenter RCT, the Branch Vein Occlusion Study (BVOS), but 2 smaller RCTs found no significant difference. The BVOS showed that scatter retinal laser photocoagulation was effective in preventing neovascularization and vitreous hemorrhage in patients with neovascularization, but a subsequent RCT found no significant effect. Randomized clinical trials evaluating intravitreal steroids (n = 2), hemodilution (n = 3), ticlopidine (n = 1), and troxerutin (n = 1) showed limited or no benefit.
There is limited level I evidence for any interventions for BRVO. The BVOS showed that macular grid laser photocoagulation is an effective treatment for macular edema and improves vision in eyes with VA of 20/40 to 20/200, and that scatter laser photocoagulation can effectively treat neovascularization. The effectiveness of many new treatments is unsupported by current evidence.
评估改善视力(VA)以及治疗视网膜分支静脉阻塞(BRVO)继发黄斑水肿和/或新生血管形成的干预措施的证据。
视网膜分支静脉阻塞是第二常见的视网膜血管疾病。
方法/文献回顾:通过检索Medline(1966年起)、Embase、Cochrane协作网、美国国立卫生研究院临床试验数据库以及视觉与眼科学研究协会年会摘要数据库(2003 - 2005年)获取英文和非英文文章。此外还通过手工检索综述文章的参考文献进行补充。两名研究者独立识别出所有随访时间超过3个月的随机临床试验(RCT)。
从检索到的4332篇文献中,识别出12项RCT。有5项关于激光光凝的RCT。在一项大型多中心RCT即视网膜分支静脉阻塞研究(BVOS)中,格栅状黄斑激光光凝对改善视力有效,但另外两项较小的RCT未发现显著差异。BVOS表明,视网膜散在激光光凝对预防新生血管形成患者的新生血管和玻璃体出血有效,但随后的一项RCT未发现显著效果。评估玻璃体内注射类固醇(n = 2)、血液稀释(n = 3)、噻氯匹定(n = 1)和曲克芦丁(n = 1)的随机临床试验显示益处有限或无益处。
对于BRVO的任何干预措施,一级证据有限。BVOS表明,黄斑格栅状激光光凝是治疗黄斑水肿的有效方法,可改善视力在20/40至20/200的眼睛的视力,且散在激光光凝可有效治疗新生血管形成。目前的证据不支持许多新治疗方法的有效性。